23andMe to go public through a merger with VG Acquisition Corp., a SPAC founded by Richard Branson, at a valuation of $3.5B
- CEO Wojcicki and SPAC leader Branson each invest $25 million — DNA-testing company has been expanding its health-care profile
Context & Ripple Effects
This announcement caps a rough private stretch for 23andMe: months earlier it had raised an ~$82.5M Series F led by Sequoia Capital and NewView Capital after laying off 14% of its workforce. Merging with VG Acquisition Corp., Richard Branson's SPAC, hands the DNA-testing company a public listing at a $3.5B valuation without a conventional IPO roadshow.
The structure carries personal conviction: CEO Anne Wojcicki and Branson each put in $25 million, while 23andMe leans into its expanding health-care profile to justify a valuation far above its consumer-kit business. As later coverage shows, this was the peak — the company went on to complete the merger and raise $600M at the same $3.5B valuation before the story turned.
First-order effects
- 23andMe gains a Nasdaq listing and public-company currency at a $3.5B valuation, with Wojcicki and Branson each committing $25 million of their own money into the transaction.
- Branson's VG Acquisition Corp. converts a two-year-old blank-check vehicle into an operating consumer-genetics company, validating his sponsor franchise.
Second-order effects
- The completed merger delivers a $600M cash infusion that funds 23andMe's push beyond DNA kits into health care — a bet that later fails to hold the valuation, which collapses from a $6B high to roughly $200M by the time Wojcicki files to take the company private.
- The headline $3.5B price sets the benchmark every subsequent 23andMe event is measured against — including the 2025 bankruptcy filing and Wojcicki's nonprofit TTAM Research Institute ultimately topping Regeneron's $305M bid for the assets.
Third-order effects
- The full arc — SPAC listing at $3.5B, collapse to ~$200M, bankruptcy, and a founder-backed nonprofit outbidding a pharma giant — becomes a template case for how 2021-vintage SPAC valuations decoupled from fundamentals, leaving public shareholders holding losses while founders retained control through the endgame.
- It also previews where consumer-genomics value actually settles: not in the listed operating company, but in the genetic database itself, contested between pharmaceutical acquirers like Regeneron and founder-aligned vehicles.
The trend: The 2021 SPAC wave handed pre-profit consumer companies headline valuations that public markets later repriced brutally, with 23andMe's path from $3.5B listing to distressed asset sale becoming one of the clearest examples.